Trials / Unknown
UnknownNCT03940001
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
A Study of Anti-PD-1 Antibody, Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Sintilimab | Other Name: (IBI308) |
| DRUG | carboplatin/paclitaxel | carboplatin AUC 2/paclitaxel 50 mg/m2 weekly |
| RADIATION | Radiation | IMRT or VMAT |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-05-01
- Completion
- 2022-05-01
- First posted
- 2019-05-07
- Last updated
- 2019-09-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03940001. Inclusion in this directory is not an endorsement.